Compound Detail
CHEMBL17860
LOFEXIDINE 💊 Approved Drug
Enter ChEMBL ID:
Free Research Context
This compound will appear in recent viewed items on the research home for this browser.
Research home
View demo workspace
💊 Approved Drug
Basic Information
| ChEMBL ID | CHEMBL17860 |
| Name | LOFEXIDINE |
| Phase | Approved |
| Structure Type | MOL |
| InChI Key | KSMAGQUYOIHWFS-UHFFFAOYSA-N |
| Therapeutic | ✓ Yes |
7
Targets
10
Activities
3
Assay Types
0
PK Parameters
20
Publications
2
Known Names
7
Indications
Molecular Properties
259.1
MW (Da)
2.76
ALogP
3
HBA
1
HBD
33.6
PSA (Ų)
0.91
QED
0
Ro5 Violations
3
Rot. Bonds
Drug Information
| Molecule Type | Small molecule |
| First Approval | 2018 |
| Availability | Prescription |
| Chirality | Racemic |
Indications
Substance-Related Disorders Opioid-Related Disorders Opioid-Related Disorders Marijuana Abuse Cocaine-Related Disorders Heroin Dependence Liver Failure
ATC Classification
N07BC04
lofexidine
Level 1: NERVOUS SYSTEM
Level 2: OTHER NERVOUS SYSTEM DRUGS
Activity Summary
Ki 5 meas. best 8.36
EC50 3 meas. best 8.86
IC50 2 meas. best 8.6
Target Activity Profile
| Target | Type | Best pChEMBL | Mean pChEMBL | Best (nM) | # Data |
|---|---|---|---|---|---|
| Alpha-2C adrenergic receptor CHEMBL1916 | EC50 | 8.86 | 8.86 | 1.4 | 1 |
| Adrenergic receptor alpha-2 CHEMBL2093864 | IC50 | 8.6 | 8.6 | 2.5 | 1 |
| Alpha-2A adrenergic receptor CHEMBL1867 | Ki | 8.36 | 8.36 | 4.4 | 1 |
| Nischarin CHEMBL5221 | Ki | 8.25 | 8.25 | 5.6 | 1 |
| Alpha-2A adrenergic receptor CHEMBL1867 | EC50 | 8.2 | 8.2 | 6.3 | 1 |
| Alpha-2B adrenergic receptor CHEMBL1942 | Ki | 7.17 | 7.17 | 67.6 | 1 |
| Alpha-2C adrenergic receptor CHEMBL1916 | Ki | 7.16 | 7.16 | 69.2 | 1 |
| Alpha-2B adrenergic receptor CHEMBL1942 | EC50 | 6.9 | 6.9 | 125.9 | 1 |
| 5-hydroxytryptamine receptor 1A CHEMBL214 | Ki | 6.9 | 6.9 | 125.9 | 1 |
| Adrenergic receptor alpha-1 CHEMBL1907610 | IC50 | 6.18 | 6.18 | 660.0 | 1 |
Activity Data Samples
Top measurements by pChEMBL value
Literature References
| PubMed | DOI | Target Context | # Activities |
|---|---|---|---|
| - | 10.5281/zenodo.13943903 | ADMET | 89 |
| 31158845 | 10.1038/s41586-019-1291-3 | ADMET | 75 |
| 22341244 | 10.1016/j.bmc.2012.01.035 | Alpha-2C adrenergic receptor | 3 |
| 22341244 | 10.1016/j.bmc.2012.01.035 | Alpha-2B adrenergic receptor | 3 |
| 22341244 | 10.1016/j.bmc.2012.01.035 | Alpha-2A adrenergic receptor | 3 |
| 37468498 | 10.1038/s41467-023-40064-9 | 5-hydroxytryptamine receptor 1A | 2 |
| 6264080 | 10.1021/jm00137a006 | Adrenergic receptor alpha | 2 |
| 37468498 | 10.1038/s41467-023-40064-9 | Muscarinic acetylcholine receptor M2 | 2 |
| 37468498 | 10.1038/s41467-023-40064-9 | 5-hydroxytryptamine receptor 2B | 2 |
| 6142954 | 10.1021/jm00370a011 | Oryctolagus cuniculus | 2 |
| 37468498 | 10.1038/s41467-023-40064-9 | Androgen receptor | 2 |
| 37468498 | 10.1038/s41467-023-40064-9 | Alpha-2A adrenergic receptor | 2 |
| 37468498 | 10.1038/s41467-023-40064-9 | 5-hydroxytryptamine receptor 2A | 2 |
| 37468498 | 10.1038/s41467-023-40064-9 | Progesterone receptor | 2 |
| - | 10.6019/CHEMBL4495565 | SARS-CoV-2 | 2 |
| - | 10.6019/CHEMBL4651402 | SARS-CoV-2 | 2 |
| 37468498 | 10.1038/s41467-023-40064-9 | Alpha-1A adrenergic receptor | 2 |
| 37468498 | 10.1038/s41467-023-40064-9 | Gamma-aminobutyric acid receptor subunit alpha-1 | 2 |
| 6094812 | 10.1021/jm00378a021 | ADMET | 1 |
| 24900506 | 10.1021/ml300064v | 5-hydroxytryptamine receptor 1A | 1 |
Data from ChEMBL 36 via Core Engine